N/A
N=107
Use of The Spanner Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men
Urinary Retention
Bottom Line
View on ClinicalTrials.gov: NCT02643849 ↗Enrolled (actual)
107
Serious AEs
14.0%
Results posted
Nov 2020
Primary outcome: Primary: Number of Participants Who Achieved Post-void Residual (PVR) of ≤150 ml Over 90 Days — 79 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- The Spanner Temporary Prostatic Stent (Device)
- Age
- Adult, Older Adult · 45+ yrs
- Sex
- Male
- Sponsor
- SRS Medical
- Primary completion
- Jan 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Achieved Post-void Residual (PVR) of ≤150 ml Over 90 Days |
79 | — |
| SECONDARY Number of Participants Who Achieved Post-void Residual (PVR) of ≤150 ml Over 30 Days |
86 | — |
Summary
The Spanner is being evaluated for use to manage voiding dysfunction and lower urinary tract symptoms in subjects to achieve bladder drainage in men unfit for other treatments.
Eligibility Criteria
Inclusion Criteria
- Age > 45 years;
- In urinary retention and catheterized (indwelling or intermittent) for less than 180 days;
- Documented diagnostic history (within 180 days of study) of detrusor contractility (>= 15 cmH2O) confirmed via pressure-flow test;
- Negative Urinalysis on Visit 1;
- Not a candidate for pharmacologic, minimally invasive or surgical treatment of the prostate;
- Charlson Weighted Index of Comorbidity Score >= 1;
- Willing and able to sign the Informed Consent Form;
- Willing and able to complete the follow-up protocol requirements;
- Experiencing catheter-induced discomfort.
Exclusion Criteria
- Current use of a urinary catheter daily for greater than 180 consecutive days immediately preceding entering into the study;
- Positive Urinalysis on Visit 1;
- Current or recent (within the last 6 months) urinary tract disease including urethral stricture, bladder stones, and other significant urological conditions or surgery;
- Surgery altering the normal uro-genital anatomy or abnormal urethral anatomy that affect the function of the lower urinary tract;
- History of conditions associated with neurogenic bladder, including spinal cord injury, multiple sclerosis, or Parkinson's disease;
- Use of anticholinergic medication;
- Gross hematuria when catheter is removed on Visit 1;
- Known or suspected prostate cancer;
- Prior pelvic irradiation therapy;
- Prostatic urethral length 9 cm (combined length from the top proximal side of the bladder neck to the bottom distal side of the external sphincter);
- Intravesical enlargement of the median lobe of the prostate.
Data sourced from ClinicalTrials.gov (NCT02643849). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.